Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  News  >  Business Leaders  >  All news

Business Leaders

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance ProfessionalsCalendarSectors 
HomeAll newsMost read newsBusiness Leaders Biography
Birthday : 08/27/1959
Place of birth : Kent - United Kingdom
Biography : Guy Hands was educated at Ravenscroft Scool in Beckington and Judd Scholl Tonbridge. He was a...
The feature you requested does not exist. However, we suggest the following feature:

Hikma Pharmaceuticals : expands licensing agreement with Rovi for their enoxaparin biosimilar

share with twitter share with LinkedIn share with facebook
share via e-mail
04/27/2018 | 10:34am CEST

London - Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the multinational pharmaceutical group, announces that it has signed a licensing agreement with Laboratorios Farmaceuticos Rovi SA (ROVI: SM) for their enoxaparin biosimilar.

Rovi's enoxaparin sodium is a biosimilar to Sanofi-Aventis' Lovenox and Clexane, which is an anticoagulant medication that belongs to low molecular weight heparin class. It is used to treat and prevent deep vein thrombosis and pulmonary embolism. As of March 2018, Rovi had achieved national authorisation for their biosimilar of enoxaparin in 16 European markets.

Under the terms of the agreement, Hikma has the exclusive rights to distribute and market enoxaparin across its MENA markets.[1]

Mazen Darwazah, Vice Chairman and CEO of MENA and Emerging Markets said, 'We are very pleased to be expanding our partnership with Rovi, adding this important cardiovascular product to our product portfolio in the MENA region. This partnership demonstrates the successful execution of our strategy to grow our biosimilar portfolio and improve patients' access to high-quality, affordable medicines'

Juan Lopez-Belmonte Encina, Rovi Chief Executive Officer said, 'Rovi is very excited to announce our recent agreement with Hikma, a global pharmaceutical company, with a strong presence across the MENA region. By leveraging Hikma's strong local presence, patients across the region will be able to access our enoxaparin biosimilar. In this new phase, together with Hikma, we aim to expand Rovi's global footprint and become a leader in the low-molecular-weight heparin field.'


Susan Ringdal

Tel: +44 (0)20 7399 2760

About Hikma

Hikma helps puts better health within reach every day for millions of people in more than 50 countries around the world. For 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. We're a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner in the MENA region, and through our venture capital arm, are helping bring innovative health technologies to people around the world.

About Rovi

Rovi is a fully integrated Spanish specialty pharmaceutical company engaged in the research, development, in-licensing, manufacturing and marketing of small molecule and specialty biologic drugs. The Company has a diversified portfolio of products that it markets in Spain through its specialized sales force, calling on specialist physicians, hospitals and pharmacies. ROVI's portfolio of 30 principal marketed products is currently anchored by the internally-developed, second generation low molecular weight heparin, Bemiparin. Rovi's research and development pipeline is focused primarily on the expansion of applications, indications and alternative mechanisms of action for the heparin-derived products and other glycosaminoglycans and on the development of new controlled release mechanisms based on ISM technology, with the aim of obtaining new pharmaceutical products that enable the regular administration of formulations which are administered daily in chronic and prolonged treatments. ROVI manufactures the active biological ingredient (Bemiparin) for its principal proprietary products and for injectable pharmaceutical products developed by its in-house research team, and utilizes its state-of-the-art filling and packaging capabilities to provide a broad array of toll manufacturing services to leading international pharmaceutical companies, primarily in the area of pre-filled syringes. In addition, ROVI provides contract manufacturing and packaging services of solid oral pharmaceutical dosage forms, using the most enhanced technology, Roller Compaction.

(C) 2018 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
1  2  3  4  5  6  7  8  9  10Next